Literature DB >> 23428961

Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion.

Babar Parvez1, M Benjamin Shoemaker, Raafia Muhammad, Rachael Richardson, Lan Jiang, Marcia A Blair, Dan M Roden, Dawood Darbar.   

Abstract

BACKGROUND: Genome-wide association studies have identified numerous common polymorphisms associated with atrial fibrillation (AF). The 3 loci most strongly associated with AF occur at chromosome 4q25 (near PITX2), 16q22 (in ZFHX3), and 1q21 (in KCNN3).
OBJECTIVE: To evaluate whether timing of AF recurrence after direct current cardioversion (DCCV) is modulated by common AF susceptibility alleles.
METHODS: A total of 208 patients (age 65 ± 11 years; 77% men) with persistent AF underwent successful DCCV and were prospectively evaluated at 3, 6, and 12 months for AF recurrence. Four single nucleotide polymorphisms--rs2200733 and rs10033464 at 4q25, rs7193343 in ZFHX3, and rs13376333 in KCNN3--were genotyped.
RESULTS: The final study cohort consisted of 184 patients. In 162 (88%) patients, sinus rhythm was restored with DCCV, of which 108 (67%) had AF recurrence at a median of 60 (interquartile range 29-176) days. In multivariable analysis, the presence of any common single nucleotide polymorphism (rs2200733, rs10033464) at the 4q25 locus was an independent predictor of AF recurrence (hazard ratio 2.1; 95% confidence interval 1.21-3.30; P = .008). Furthermore, rs2200733 exhibited a graded allelic dose response for early AF recurrence (homozygous variants: 7 [interquartile range 4-56] days; heterozygous variants: 54 [28-135] days; and wild type: 64 [29-180] days; P = .03).
CONCLUSIONS: To our knowledge, this is the first study to evaluate whether genomic markers can predict timing of AF recurrence in patients undergoing elective DCCV. Our findings show that a common polymorphism on chromosome 4q25 (rs2200733) is an independent predictor of AF recurrence after DCCV and point to a potential role of stratification by genotype.
Copyright © 2013 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23428961      PMCID: PMC3690553          DOI: 10.1016/j.hrthm.2013.02.018

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  28 in total

Review 1.  Conserved and divergent mechanisms in left-right axis formation.

Authors:  R D Burdine; A F Schier
Journal:  Genes Dev       Date:  2000-04-01       Impact factor: 11.361

2.  Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation.

Authors:  Babar Parvez; Joseph Vaglio; Shane Rowan; Raafia Muhammad; Gayle Kucera; Tanya Stubblefield; Shannon Carter; Dan Roden; Dawood Darbar
Journal:  J Am Coll Cardiol       Date:  2012-06-20       Impact factor: 24.094

3.  PITX2c is expressed in the adult left atrium, and reducing Pitx2c expression promotes atrial fibrillation inducibility and complex changes in gene expression.

Authors:  Paulus Kirchhof; Peter C Kahr; Sven Kaese; Ilaria Piccini; Ismail Vokshi; Hans-Heinrich Scheld; Heinrich Rotering; Lisa Fortmueller; Sandra Laakmann; Sander Verheule; Ulrich Schotten; Larissa Fabritz; Nigel A Brown
Journal:  Circ Cardiovasc Genet       Date:  2011-01-31

4.  Pitx2c and Nkx2-5 are required for the formation and identity of the pulmonary myocardium.

Authors:  Mathilda T M Mommersteeg; Nigel A Brown; Owen W J Prall; Corrie de Gier-de Vries; Richard P Harvey; Antoon F M Moorman; Vincent M Christoffels
Journal:  Circ Res       Date:  2007-09-06       Impact factor: 17.367

5.  Meta-analysis identifies six new susceptibility loci for atrial fibrillation.

Authors:  Patrick T Ellinor; Kathryn L Lunetta; Christine M Albert; Nicole L Glazer; Marylyn D Ritchie; Albert V Smith; Dan E Arking; Martina Müller-Nurasyid; Bouwe P Krijthe; Steven A Lubitz; Joshua C Bis; Mina K Chung; Marcus Dörr; Kouichi Ozaki; Jason D Roberts; J Gustav Smith; Arne Pfeufer; Moritz F Sinner; Kurt Lohman; Jingzhong Ding; Nicholas L Smith; Jonathan D Smith; Michiel Rienstra; Kenneth M Rice; David R Van Wagoner; Jared W Magnani; Reza Wakili; Sebastian Clauss; Jerome I Rotter; Gerhard Steinbeck; Lenore J Launer; Robert W Davies; Matthew Borkovich; Tamara B Harris; Honghuang Lin; Uwe Völker; Henry Völzke; David J Milan; Albert Hofman; Eric Boerwinkle; Lin Y Chen; Elsayed Z Soliman; Benjamin F Voight; Guo Li; Aravinda Chakravarti; Michiaki Kubo; Usha B Tedrow; Lynda M Rose; Paul M Ridker; David Conen; Tatsuhiko Tsunoda; Tetsushi Furukawa; Nona Sotoodehnia; Siyan Xu; Naoyuki Kamatani; Daniel Levy; Yusuke Nakamura; Babar Parvez; Saagar Mahida; Karen L Furie; Jonathan Rosand; Raafia Muhammad; Bruce M Psaty; Thomas Meitinger; Siegfried Perz; H-Erich Wichmann; Jacqueline C M Witteman; W H Linda Kao; Sekar Kathiresan; Dan M Roden; Andre G Uitterlinden; Fernando Rivadeneira; Barbara McKnight; Marketa Sjögren; Anne B Newman; Yongmei Liu; Michael H Gollob; Olle Melander; Toshihiro Tanaka; Bruno H Ch Stricker; Stephan B Felix; Alvaro Alonso; Dawood Darbar; John Barnard; Daniel I Chasman; Susan R Heckbert; Emelia J Benjamin; Vilmundur Gudnason; Stefan Kääb
Journal:  Nat Genet       Date:  2012-04-29       Impact factor: 38.330

6.  Prevention of atrial fibrillation: report from a national heart, lung, and blood institute workshop.

Authors:  Emelia J Benjamin; Peng-Sheng Chen; Diane E Bild; Alice M Mascette; Christine M Albert; Alvaro Alonso; Hugh Calkins; Stuart J Connolly; Anne B Curtis; Dawood Darbar; Patrick T Ellinor; Alan S Go; Nora F Goldschlager; Susan R Heckbert; José Jalife; Charles R Kerr; Daniel Levy; Donald M Lloyd-Jones; Barry M Massie; Stanley Nattel; Jeffrey E Olgin; Douglas L Packer; Sunny S Po; Teresa S M Tsang; David R Van Wagoner; Albert L Waldo; D George Wyse
Journal:  Circulation       Date:  2009-02-03       Impact factor: 29.690

7.  Common variants in KCNN3 are associated with lone atrial fibrillation.

Authors:  Patrick T Ellinor; Kathryn L Lunetta; Nicole L Glazer; Arne Pfeufer; Alvaro Alonso; Mina K Chung; Moritz F Sinner; Paul I W de Bakker; Martina Mueller; Steven A Lubitz; Ervin Fox; Dawood Darbar; Nicholas L Smith; Jonathan D Smith; Renate B Schnabel; Elsayed Z Soliman; Kenneth M Rice; David R Van Wagoner; Britt-M Beckmann; Charlotte van Noord; Ke Wang; Georg B Ehret; Jerome I Rotter; Stanley L Hazen; Gerhard Steinbeck; Albert V Smith; Lenore J Launer; Tamara B Harris; Seiko Makino; Mari Nelis; David J Milan; Siegfried Perz; Tõnu Esko; Anna Köttgen; Susanne Moebus; Christopher Newton-Cheh; Man Li; Stefan Möhlenkamp; Thomas J Wang; W H Linda Kao; Ramachandran S Vasan; Markus M Nöthen; Calum A MacRae; Bruno H Ch Stricker; Albert Hofman; André G Uitterlinden; Daniel Levy; Eric Boerwinkle; Andres Metspalu; Eric J Topol; Aravinda Chakravarti; Vilmundur Gudnason; Bruce M Psaty; Dan M Roden; Thomas Meitinger; H-Erich Wichmann; Jacqueline C M Witteman; John Barnard; Dan E Arking; Emelia J Benjamin; Susan R Heckbert; Stefan Kääb
Journal:  Nat Genet       Date:  2010-02-21       Impact factor: 38.330

Review 8.  Role of inflammation in initiation and perpetuation of atrial fibrillation: a systematic review of the published data.

Authors:  Tim T Issac; Hisham Dokainish; Nasser M Lakkis
Journal:  J Am Coll Cardiol       Date:  2007-11-05       Impact factor: 24.094

9.  Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications.

Authors:  W M Feinberg; J L Blackshear; A Laupacis; R Kronmal; R G Hart
Journal:  Arch Intern Med       Date:  1995-03-13

10.  Short-term and long-term success of electrical cardioversion in atrial fibrillation in managed care system.

Authors:  Suman S Kuppahally; Elyse Foster; Stanford Shoor; Anthony E Steimle
Journal:  Int Arch Med       Date:  2009-12-12
View more
  33 in total

Review 1.  Genome-wide association studies of late-onset cardiovascular disease.

Authors:  J Gustav Smith; Christopher Newton-Cheh
Journal:  J Mol Cell Cardiol       Date:  2015-04-11       Impact factor: 5.000

Review 2.  Cardiovascular pharmacogenomics: current status and future directions.

Authors:  Dan M Roden
Journal:  J Hum Genet       Date:  2015-07-16       Impact factor: 3.172

Review 3.  Emerging directions in the genetics of atrial fibrillation.

Authors:  Nathan R Tucker; Patrick T Ellinor
Journal:  Circ Res       Date:  2014-04-25       Impact factor: 17.367

Review 4.  The Role of Pharmacogenetics in Atrial Fibrillation Therapeutics: Is Personalized Therapy in Sight?

Authors:  Dawood Darbar
Journal:  J Cardiovasc Pharmacol       Date:  2016-01       Impact factor: 3.105

Review 5.  Genetics of atrial fibrillation: from families to genomes.

Authors:  Ingrid E Christophersen; Patrick T Ellinor
Journal:  J Hum Genet       Date:  2015-05-21       Impact factor: 3.172

Review 6.  Genotype influence in responses to therapy for atrial fibrillation.

Authors:  Henry Huang; Dawood Darbar
Journal:  Expert Rev Cardiovasc Ther       Date:  2016-07-15

7.  Association of atrial fibrillation risk alleles and response to acute rate control therapy.

Authors:  Tyler W Barrett; Wesley H Self; Dawood Darbar; Cathy A Jenkins; Brian S Wasserman; Natasha A Kassim; Michael Casner; M Benjamin Shoemaker
Journal:  Am J Emerg Med       Date:  2016-02-10       Impact factor: 2.469

8.  Strategies for Risk Analysis and Disease Classification in Atrial Fibrillation.

Authors:  Sara Adelman; Georges Daoud; Peter J Mohler
Journal:  J Cardiovasc Electrophysiol       Date:  2016-09-20

Review 9.  Common variation in atrial fibrillation: navigating the path from genetic association to mechanism.

Authors:  Nathan R Tucker; Sebastian Clauss; Patrick T Ellinor
Journal:  Cardiovasc Res       Date:  2016-01-04       Impact factor: 10.787

Review 10.  Genetic mechanisms of atrial fibrillation: impact on response to treatment.

Authors:  Dawood Darbar; Dan M Roden
Journal:  Nat Rev Cardiol       Date:  2013-04-16       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.